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LDL-Apheresis Atherosclerosis 
Regression Study (LAARS)
Effect of Aggressive Versus Conventional Lipid Lowering 
Treatment on Coronary Atherosclerosis
Abraham A. Kroon, MD; Wim R.M. Aengevaeren, MD; Tjeerd van der Werf, MD; Gerard J.H. Uijen, PhD;
Johan H.C. Reiber, PhD; Albert V.G. Bruschke, MD; Anton F.H. Stalenhoef, MD
Background Intensive lipid lowering may retard the  p ro­
gression of coronary atherosclerosis. LDL-apheresis has the 
potential to decrease L D L  cholesterol to very low levels. To 
assess the effect of m ore aggressive lipid lowering with LDL- 
apheresis, we set up a randomized study in men with hyper­
cholesterolemia and severe coronary atherosclerosis.
Methods and Results For 2 years, 42 men were treated with 
either biweekly LDL-apheresis plus medication or medication 
alone. In both groups a dose of simvastatin of 40 mg per day was 
administered. Baseline (m ean±SD ) LDL cholesterol was 7.8 ±1.9 
mmol - L  l and 7.9±2.3 mmol * L~! in the apheresis and medica­
tion groups, respectively. The mean reduction in LDL cholesterol 
was 63% (to 3.0 mmol * L“ 1) and 47% (to 4.1 mmol • L _l), 
respectively. Primary quantitative coronary angiographic end 
points were changes in average mean segment diameter and 
minimal obstruction diameter. N o differences between the 
apheresis and medication groups were found in mean segment 
diameter (-0 .01  ±0.16 mm versus 0.03 ±0.16 mm, respectively)
T he relation between total cholesterol and LDL cholesterol levels and the incidence of CAD is well established.1’2 Primary and secondary pre­vention trials, predominantly conducted in men with 
hypercholesterolemia, have shown that lipid lowering 
regimens result in less progression of angiographic le­
sions.3 Regression of coronary atherosclerosis is demon­
strated to a limited extent in some patients in most of 
these trials.4-12 The common denominator of these trials 
is reduction of LDL cholesterol,13 Until recently, inten­
sive lipid lowering in men with established CAD using 
HMG-CoA reductase inhibitors was the most effective 
means in terms of slowing or arrest of progression of 
coronary atherosclerosis14’15 and consequently reducing 
the number of clinical events.16
Continuous LDL-apheresis, using dextran sulfate cellu­
lose columns, selectively removes apolipoprotein B-con­
taining lipoproteins from plasma.17*18 The performance of
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or in minimal obstruction diameter (—0.01 ±0.13 mm versus
0.01 ±0.11 mm, respectively), expressed as means per patient. On 
the basis of coronary segment, mean percent stenosis of all lesions 
showed a tendency to decrease; only in the apheresis group more 
minor lesions disappeared in comparison to the medication group. 
On bicycle exercise tests, the time to 0,1 mV ST-segment depres­
sion increased significantly by 39% and the maximum level of ST 
depression decreased significantly by 0.07 mV in the apheresis 
group versus no changes in the medication group.
Conclusions Two years of lipid lowering both with medica­
tion alone or LDL-apheresis with medication showed angio­
graphic arrest of the progression of coronary artery disease. 
However, m ore aggressive treatment induced functional im­
provement, which may precede anatomic changes. (Circulation. 
1996;93:1826-1835.)
Key Words •  angiography • atherosclerosis • coronary 
disease •  apheresis •  lipids •  lipoproteins
regular apheresis permits the achievement of lower levels 
of LDL cholesterol, which is not usually possible to attain 
with drug therapy alone. The application of this method 
may offer opportunities in the prevention of progression or 
even inducing regression of coronary atherosclerosis in 
selected patients with primary hyperlipidemia and estab­
lished CAD.19-22
The quantitative computerized analysis of the extent 
of atherosclerosis on QCA has been developed and 
extensively evaluated for angiographic trials,23*25 Despite 
certain limitations, QCA is one of the most precise 
procedures available for assessing progression or regres­
sion of CAD.26 Given the relatively small changes in the 
severity of lesions demonstrated in angiographic trials 
and the unclear clinical benefits of such changes, the 
addition of measurements to predict the functional 
significance of changes in coronary stenosis seems 
important.27
The LDL-Apheresis Atherosclerosis Regression Study 
(LAARS) was designed as a prospective, open, random­
ized, single-center study in men with primary hypercholes­
terolemia and extensive CAD. The objective was to deter­
mine whether more aggressive LDL cholesterol lowering, 
with biweekly LDL-apheresis plus the HMG-CoA reduc­
tase inhibitor simvastatin, more effectively exerts an anti- 
atherosclerotic effect than lipid lowering to more conven­
tional cholesterol levels with simvastatin alone. In this 
article, the results of sequential exercise tolerance tests and
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Selected Abbreviations and Acronyms
apo = apolipoprotein 
CABG = coronary artery bypass graft 
CAD = coronary artery disease 
Lp(a) = iipoprotein(a)
MOD = minimal obstruction diameter 
MSD = mean segment diameter
PTCA = percutaneous transluminal coronary angioplasty 
QCA -  quantitative coronary angiogram
quantitative computer-assisted analysis of coronary angio­
grams during 2 years of treatment are described and 
related to the lipid and lipoprotein levels. The results of 
functional measurements of coronary blood flow by means 
of videodensitometry will be presented separately.
Methods
Subjects and Treatment
From January 1990 until May 1992, m en aged between 30 
and 67 years who underwent diagnostic coronary angiography 
for angina pectoris were screened for eligibility. Included were 
patients with a mean of two successive serum total cholesterol 
determinations >8.0 mmol • L “1 or LD L cholesterol >5.8 
mmol ■ L "1 and a mean of two successive fasting serum triglyc­
eride measurements <5.0 mmol • L “1 on a standard lipid 
lowering diet without other lipid lowering treatments and 
extensive coronary atherosclerosis as shown by visual assess­
m ent of their coronary angiogram. Excluded were patients with 
a ventricular ejection fraction <0.35; acute myocardial infarc­
tion, PTCA, or CABG within the previous 3 months; impaired 
hepatic (> 30%  above normal range) or renal function (plasma 
creatine ^ 1 5 0  fimol * L _1); hypertension (diastolic blood pres­
sure >100 mm Hg); diabetes mellitus; severe obesity (BMI 
> 3 0  kg • m~2); homozygous familial hypercholesterolemia; any 
secondary hyperlipidemia; and heavy smokers (> 1 0  cigarettes 
per day). Patients with a histoiy of PT C A  and CABG were 
included because these modalities have become an integral 
part of the treatment of patients with CAD. Excluding these 
patients would have introduced a  selection bias. Patients both 
with and without PTCA or CABG had severe coronary a thero­
sclerosis to the same degree (Table 1).
A t least 2 months before the start of the study, all lipid 
lowering drugs were stopped. Only a cholesterol lowering diet 
equivalent to the American H eart Association step I diet was 
continued or prescribed, and the patients were instructed by a 
dietitian. During this 2-month run-in period, an exercise test 
and coronary angiography were performed. Written informed 
consent according to the Declaration of Helsinki was obtained. 
Those patients who met all inclusion and exclusion criteria 
were allocated at random to either biweekly LDL-apheresis 
plus simvastatin (40 mg/d), a potent H M G -C oA  reductase 
inhibitor,28’29 or simvastatin treatm ent (40 mg/d) alone. R an ­
domization was stratified for the level of serum total cholester­
ol and Lp(a), age, and CABG status.
LDL-apheresis was performed with an autom ated system 
with two small-sized dextran sulfate cellulose columns (MA-01 
unit, Kanegafuchi Chemical Industry Co Ltd). In this system, 
the plasma is separated by a polysulfone m em brane separator, 
and apolipoprotein B-containing particles are adsorbed in one 
of two columns containing cellulose-bound dextran sulfate used 
in rotation in a veno-venous extra corporeal circuit. A  volume 
of 5000 mL («**1.5 plasma volume) was treated per session. The 
combination therapy of LDL-apheresis and simvastatin can be 
expected to slow down the postapheresis rebound in serum 
cholesterol, which permits prolongation o f  the intervals be­
tween the apheresis procedures.30*31 Patients allocated to lipid 
lowering with drugs attended the outpatient clinic each month; 
those on LDL-apheresis were seen fortnightly. In  both groups,
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Ta b le  1. Baseline Characteristics
Apheresis
(n=21)
Medication 
Only (n=21) p#
Age, y 50.2±9.6 53.9±8.7 .43
Weight, kg 81.5±9.7 80.8±8.6 .88
Body mass index, kg • m“ 2 26.6±2.0 26.2±2.0 .64.
Blood pressure, mm Hg
Systolic 129.3±17.3 126.3±18.1 .56
Diastolic 78.2±8.9 76.5±9.0 .63
Current smoking 3 (14.3) 4(19.0) 1.00
Vascular disease
Infarction 16 (76.2) 18 (85.7) .69
CABG 10 (47.6) 10 (47.6) .75
PTCA 2 (9.5) 5 (23.8) .41
Hypertension 2 (9.5) 5 (23.8) .41
Stroke 1 (4.8) 3(14.3) .60
Claudication 3 (14.3) 5 (23.8) .69
Drug treatment
/3-Blocker 10 (47.6) 14 (66.7) .35
Ca channel blockers 4 (19.0) 7 (33.3) .48
Long-acting nitrates 4 (19.0) 4 (19.0) .69
Anticoagulants 3 (14.3) 6 (28.6) .45
Platelet aggregation
inhibitors 4 (19.0) 8 (38.1) .31
Values indicate numbers (percentages) or meanrtSD. 
*t test or x 2 test where appropriate.
a resin in the highest tolerable doses was added to the 
trea tm ent if (preapheresis) serum cholesterol levels for 2 
consecutive m onths rem ained  >8.0 mmol • L“1, since it was 
considered inappropria te  to continue single drug treatment 
above this level. A t each visit, the patients were subjected to a 
brief physical examination, and additional dietaiy instruction 
was repeated  frequently. Antianginal medication was contin­
ued at the sam e doses during the study. If adaptation was 
necessary during the study, the original prescription, if possible, 
was restored before  thè  follow-up heart catheterization.
Lipids, Lipoproteins, and Laboratory 
Safety Measures
In both  groups lipids, lipoproteins, b lood chemistry, hem o­
grams, and  rou tine  urinalysis were performed monthly. Apo 
A l ,  apo B, and  Lp(a) were measured bimonthly. In the 
apheresis group, lipids and lipoproteins and  some extra labo­
ratory safety param eters  (hemogram, calcium, and total protein 
level) w ere  m easu red  b e fo re  and im m ediately  after each 
LDL-apheresis. Serum total cholesterol and fasting triglycer­
ides were determ ined enzymatically (C H O D -PA P, No. 237574, 
Boehringer Mannheim Gm bH, and Sera-PAK, No. 6639, Miles). 
H D L  cholesterol was determ ined  with the  polyethylene glycol 
6000 precipitation m ethod .32 LDL cholesterol was calculated 
by subtraction. Samples for apo A l,  apo  B, and Lp(a) were 
stored at ~80°C  and determ ined  at the end  of the study. Apo 
A l  and apo B were quantified in serum by immunonephelom- 
etry.33 Lp(a) was m easured  by a specific radioimmunoassay 
(apo[a] R IA  100, Pharm acia  Diagnostics AB). Hyperhomocys- 
teinemia was excluded by measuring fasting homocysteine 
levels.34 Fibrinogen levels did not differ between both groups. 
Apheresis produced an acute 35% reduction o f  fibrinogen, 
returning to p re trea tm en t levels between 2 and 7 days ( n = l l ,  
data  not shown).
T he  selective removal o f  apo  B -contain ing  lipoproteins with 
LDL-apheresis causes sawtoothlike alterations in lipoprotein 
concentrations.35 The increase of lipoprotein levels after the 
trea tm ent can be explained by first-order kinetics.36*38 T here­
fore, time-averaged concentrations (CAVG) or interval means of 
total cholesterol, L D L  cholesterol, apo B, and Lp(a) were 
calculated by applying a formula derived from the rebound 
curves tha t  w ere  constructed for each patient at one occasion:
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Cavg—Cmin 0.73 (CMAx Cmin)
where CMAX is the p re trea tm ent level and CMIN the levels 
immediately after apheresis.39 F or serum triglycerides and 
PIDL cholesterol, only p re trea tm en t levels were used in the 
analysis because triglycerides reach p re trea tm ent levels within 
1 to 2 days after apheresis and H D L  cholesterol is not 
influenced by LDL-apheresis.
Exercise Tests
Bicycle exercise tests were perform ed at baseline and 12 and 
24 months after the start of the  study. T h e  assessments at the 
end of the study were done 3 to 4 weeks after the last apheresis. 
An electronic b raked  ergom eter (M arquette  Case 15, M ar­
quette Electronics Inc) was used, starting at a load of 50 W and 
raising it every minute by 10 W  during continuous ECG 
monitoring to maximum exercise limited by chest discomfort or 
usual criteria for stopping the test. Blood pressure and 12-lead 
ECG registration were m onitored at rest, at maximum exercise, 
and every minute during the test. A utom ated  calculation of 
ST-segment depression was perform ed at a point located 80 ms 
beyond the J~point. D a ta  were corrected for the systolic blood 
p ressure-heart  ra te  product at maximal load. A n additional 
exercise thallium scintigram was perform ed when the bicycle 
exercise test was not conclusive due to a maximum heart 
frequency < 85%  of the predicted value corrected for age and 
body mass and/or the predicted  load s 8 0 % without ST- 
segment changes.
Coronary Angiography
The coronary angiograms w ere obtained at baseline and 
after 2 years of treatm ent, 4 weeks after the last apheresis, 
using the same protocol as tha t  described for the Regression 
Growth Evaluation Statin Study (R E G R E S S ).12 During both 
procedures, the same nonionic iso-osmolar contrast agent 
(Iohexol 350, Nycomed AS) and the same cineangiographic 
techniques were used, according to standard requirements for 
quantitative analysis.25 A  centim eter grid was filmed to adjust 
for pincushion distortion. The same type and diameter of 
catheters were used in both procedures and were used as a 
scaling device in Q C A  analysis. The protocol required admin­
istration of 5 to 10 mg of isosorbide dinitrate sublingually 5 
minutes before the first intracoronary injection of contrast, 
which was repeated during the  p rocedure  if necessary. Twelve 
to 15 coronary segments w ere filmed in two projections.411 
Preferably, end-diastolic frames were selected for blinded 
computer-assisted quantitative analysis o f  paired angiograms, 
which was performed at the H eart  Core Angiographic Refer­
ence Laboratory at the University Hospital of Leiden using the 
Cardiovascular M easurem ent System (CMS Medis Medical 
Imaging Systems, CMS version 2.3D).41 This system uses a 
high-quality cinevideo converter (CAP 35E) that allows a 
selected cineframe to be projected onto  a digital camera 
through a zoom lens (magnification X2.3). The video signal of 
the magnified region was digitized a t  a matrix size of 
512X512X8 bits. For calibration, the boundaries of a nonta­
pering part of the catheter were determ ined automatically over 
a length of approximately 2 cm. To assess the contours of the 
vessel, the beginning and the  end of the specific coronary 
segment had to be indicated, after which a path line was 
computed connecting these two points. The contours of the 
vessel were then com puted in multiple iterations by the mini­
mal cost contour detection technique. T he  edge strength of a 
point was based on the weighted sum of the first and second 
derivative functions; this edge strength was coi'rected for the 
limited resolution o f  the  entire imaging chain, a  procedure that 
is particularly im portant for the  accurate measurement of small 
vessels. A  diam eter function was determ ined in absolute terms 
(in millimeters) by computing the  shortest distances between 
the left and right contours along the vessel centerline. The 
reference diam eter was defined as previously described.42
Primarily, M OD, as a measure for localized atherosclerosis, 
and the MSD, as a measure for diffuse changes, were assessed. 
Only segments without overlap and minimal foreshortening 
were analyzed, including bypass segments. PTCA segments 
from procedures after the randomization and segments distal 
to an occlusion were excluded from  analysis. Patients were 
categorized with regard to MOD and clinical events as regres­
sors, stable patients, and progressors, according to the 
REG RESS protocol.12 Patients with at least one lesion wors­
ening by ^ 0 .4  mm or development of a lesion that reduced the 
lumen diameter by sO.4 mm were defined as progressors. 
Regressors were patients with at least one lesion improving 
^0 .4  mm and no lesions worsening ^0 .4  mm. Stable patients 
had no lesions worsening or improving by ^0 .4  mm. Patients 
with regressing and progressing lesions were considered to be 
progressors because simultaneous progression and regression 
reflect an unstable process in coronary atherosclerosis.10 If a 
patient previously had a myocardial infarction or unstable 
angina, he was considered to be a progressor irrespective of 
angiographic outcome, Additionally, the percentage of steno­
ses in each segment was calculated as the mean of the percent 
stenosis in two projections, ensuring comparability of the 
segments by available angiographic landmarks, in the baseline 
and follow-up angiograms. Only segments with a mean percent­
age of stenosis ^ 2 0 %  at either baseline or follow-up were 
analyzed. If only one projection was available of a stenosis 
^20% , this figure was used as the m ean percent stenosis in that 
particular angiogram. New lesions were defined as <20%  at 
baseline and > 2 0 %  at follow-up.
Statistical Analysis
The sample size was limited for logistic reasons to approxi­
mately 40 patients. At the start of the study, the observed 
standard deviation for mean progression in coronary segments 
from previous trials was 0.23 to 0.32 mm (0.32 mm with 
baseline total cholesterol >6.00 mmol • L“1). Considering the 
expected changes in cholesterol levels, a minimal sample size of 
19 patients in each group was calculated (SD=0.25 mm, 
expected difference—0.20 mm).25
Analyses were performed with procedures available in the 
Statistical Package for Social Sciences (SPSS Inc) with use of 
the Student’s t test and multivariate A N O V A  (with correction 
for repeated measures or covariates) for normally distributed 
data or the Mann-Whitney U test for differences in means of 
not normally distributed data. Differences in proportions were 
analyzed with the (Yates’) corrected x 2 test, and analyses for 
trends in proportions were performed with the extended Man- 
tel-Haenszel x 2 test. A two-sided Fisher’s exact test was used 
when the total number of cases was less than 15. For measures 
of agreement, the Pearson product-moment correlation coef­
ficient was used. Analyses were based on randomization assign­
ment, except for one patient in the apheresis group, who died 
within 3 months from the start of the study. A two-sided 
probability value of <.05 was considered significant. Results 
are expressed as m ean± S D  unless otherwise indicated.
Results 
Baseline Characteristics
In both treatment groups, 21 men were enrolled for 
whom baseline characteristics are shown in Table 1. In 
both groups, 16 patients were heterozygous for familial 
hypercholesterolemia (76% of the study population). 
Risk factors for atherosclerosis were equally distributed. 
All patients had severe coronary atherosclerosis. A 
previous history of myocardial infarction was present in 
16 versus 18 men in the apheresis and medication 
groups, respectively, and CABG had been performed in 
10 men in both groups. By the criterion of a stenosis of 
^50% being considered significant, 17 of 21 men in the
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Table 2. Changes in Lipids and Lipoproteins: Baseline and Treatment Levels
Apheresis (n=:21) Medication Only (n=21) Difference
Basal Before After
Interval
Mean
%
Change Basal Mean
%
Change P
Total
cholesterol, 
mmol ♦ L~' 9.72±1.84 5.60+1.26 2.06±0,46 4.63+1.18 -52.9±6.6 9.85+2.17 5.95+1.60 -39.5±7.7 .005
Triglycerides, 
mmol • L~1 2.32 + 1.03 1.83+0.76 0.48±0,28 1.83+0.76 —17.4±24.4 2.64 + 1.33 1.84+0.89 -26.5+20.3 .38
LDL
cholesterol, 
mmol • L~1 7.78±1.86 3.72±1,26 0.82+0.41 2.95+1.13 -62.9 + 8.3 7.85 + 2.34 4.13+1.58 —47.4±8.1 .01
HDL
cholesterol, 
mmol • L-1 0,93±0.18 1.09±0.20 1.08+0.20 1.09+0.20 + 17.7±13.6 0.92±0.19 1.05+0.22 + 13.7+10.9 .23
Lipoprotein(a),
mg-dL‘ 1 57.0±63.9 59,1+68.8 13.8+15.3 44.5+54.3 -18.6 + 18.0 38.4±39.7 44.5+45.7 + 14.9+16,3 .02
Apolipoprotein 
A1, g • L~1 1.43±0.29 1.34+0.17 1.08+0.13 1.34±0.17 -5 .3  + 13.0 1.46 + 0.38 1.33+0.21 -5.4+16.8 .89
Apolipoprotein
B.g -L - ' 2.59±0.47 1.65+0.43 0.45+0.16 1.32 ±0.35 -49.0±7.6 2.60 + 0.61 1.74±0.47 -31.0+17.0 .003
Data are mean±SD. Apheresis group: 52 measurements per patient. Medication group: 26 measurements per patient. Before indicates pretreatment 
levels (CMA><); after, posttreatment levels (CM|N); interval mean, time-averaged levels (CAVq), calculated as follows: CAvq~CM|N+0.73(CMAx~CM|N) (see text); % 
change, difference between basal and mean levels; P, probability values of differences between interval mean in the apheresis group and mean levels in 
the medication group {t test or Mann-Whitney U test where appropriate). To convert values for total cholesterol to mg/dL, multiply by 38.67; to convert 
values for triglycerides to mg/dL, multiply by 88.57.
apheresis group and 19 of 21 men in the medication 
group had three-vessel disease of the coronary arteries, 
and the other patients had two-vessel disease. Drug 
treatment at randomization showed a higher but not 
statistically significant number of patients in the medi­
cation group using anticoagulants or platelet aggrega­
tion inhibitors (Table 1). At the time the study started, 
anticoagulants or platelet inhibitors were used less. 
Baseline cholesterol levels were high, and predominant 
elevation of apo B-containing lipoproteins was found in 
agreement with the inclusion criteria (Table 2). Lp(a) 
levels showed a skewed distribution, with median base­
line levels of 28.8 and 19.8 mg • dL“] in the apheresis 
and medication groups, respectively. The treatment 
groups were well balanced, and no significant differences 
were found with respect to baseline characteristics and 
baseline lipid and lipoprotein concentrations.
Clinical Events and Patient Evaluation
Three patients in the apheresis group and 5 in the 
medication group had to be hospitalized for unstable 
angina (Table 3). One of the patients in the apheresis 
group was lost to follow-up because of death immedi­
ately after coronary surgery within 3 months after the
Table 3. Clinical Events
Apheresis
Medication
Only P*
Hospitalization for unstable angina 3 5 .69
PTCA (1) (1) .47
CABG (2)t (1) 1.00
Nonfatal myocardial infarction 4 0 .11
Death 1 0 1.00
Claudication 2 2 .60
PTCA (1) (0) 1.00
CABG (0) (1) 1.00
Stroke/transient ischemic attack 0 1 1.00
Numbers in parentheses represent a subdivision, eg, 1 of the 3 patients 
hospitalized for angina had a PTCA.
*X2 test; tone patient died.
start of the study. From the other two patients in the 
apheresis group with unstable angina, one had to un­
dergo CABG at 9 months after the start of the study and 
continued only treatment with simvastatin after this 
procedure; the other one had to undergo a PTCA 
procedure at 12 months and continued treatment with 
LDL-apheresis afterward. Four men in the apheresis 
group had a myocardial infarction, all within 6 months 
(range, 2 to 6) after the start of the study. In all these 
patients, LDL-apheresis and simvastatin treatment were 
continued. Unstable angina in the medication group was 
observed 5 to 24 months after the start of the study, 
causing hospitalization and adjustment of antianginal 
drugs, and two interventions (PTCA and CABG) at the 
end of the study. A total of seven cardiac events (unsta­
ble angina and infarction) in seven different patients in 
the apheresis group versus five events in five different 
patients in the medication group was observed (P - .73). 
Most events took place in the first year of treatment, 
with a median of 5 versus 5.5 months after the start of 
the study in the apheresis and medication groups, re­
spectively. There were no significant differences between 
both groups (Table 3).
Lipid and Lipoprotein Profiles
Three patients in the apheresis group and four in the 
medication group received additional resin treatment, 8 
to 24 g cholestyramine per day. LDL-apheresis caused 
an acute reduction of 62%, 78%, 71%, and 72% of the 
mean concentrations of total cholesterol, LDL choles­
terol, Lp(a), and apo B, respectively (Table 2). HDL 
cholesterol levels were not influenced by this procedure, 
and apo A l levels were acutely decreased on the average 
by 20%. Pretreatment levels of total cholesterol, triglyc­
erides, LDL cholesterol, HDL cholesterol, apo A l, and 
apo B in the apheresis group were not significantly 
different in comparison to mean levels in the medication 
group. Pretreatment levels of Lp(a) in the apheresis 
group did not change compared with basal concentra­
tions, whereas an increase of 15% (P - .03) in the
Table  4. Bicycle Exercise Electrocardiography at Baseline, After 1 Year, and After 2 Years of Treatment
1830 Circulation Vol 93, No 10 May 15, 1996
Apheresis (n== 17) Medication Only (n=15) Difference
Test 1 Test 2 Test 3 Pa Test 1 Test 2 Test 3 Pm Pd
Ex-time, s 687±36 674±43 702±41 0.34 687±65 630±44 667±60 0.19 0.21
ST-time, s 461 ±47 548±51 641 ±50 0.001 485±81 464±54 442±60 0.52 0.001
ST-max, mm 1.4±0.2
CM
•
O■H00
•
o
0.7±0.2 0.000 1.4±0.3 1.3±0.3 1.4±0.4 0,76 0,008
Sbphr-max, 
mm Hg/min 29 842 ±2020 29 089±1311 29 458±1549 0.89 27 141 ±1518 26 090±1015 26 119±1169 0.60 0.84
Load-max ,W 151 ±6 152 ±7 157±7 0,46 154±10 147±7 151 ±10 0.29 0.30
Data are mean±SEM. Tests 1, 2, and 3 indicate exercise test at baseline, after 1 year, and after 2 years of treatment, respectively; Ex-time, maximal 
exercise time; ST-time, time to 1 mm (=0.1 mV) ST depression; ST-max, maximal ST depression; Sbphr-max, systolic blood pressure-heart rate product 
at maximal exercise; Load-max, maximal load; and PA, PM, and PD) probability values in Apheresis (A) and Medication (M) groups, and of the difference 
(D) between Apheresis and Medication groups, respectively (multivariate ANOVA).
medication group, was found. Differences in treatment 
effects were established by comparison of interval mean 
concentrations in the apheresis group and mean concen­
trations in the medication group, During the entire 
course of the study, a constant reduction of 63% of LDL 
cholesterol was found in the apheresis group to an 
interval mean level of 2.95±1.13 mmol ■ L“1. Total 
cholesterol, LDL cholesterol, and apo B showed the 
same course and were significantly lower in comparison 
to the medication group (Table 2). HDL cholesterol 
levels at baseline and during the study were comparable 
in both groups; an increase of 14% to 18% was observed 
while on treatment with simvastatin (Table 2). Although 
significantly reduced, the mean serum triglyceride levels 
showed no differences between the groups. The LDL/ 
HDL cholesterol ratio was reduced from 8.4 to 2.7 
(-68% ) in the apheresis group versus 8.5 to 3,9 (-54% ) 
in the medication group, respectively. Time-averaged 
Lp(a) levels were reduced by 19% in the apheresis 
group, which were significantly different in comparison 
with increased levels found in the medication group 
(Table 2).
Exercise Tests
Seventeen and 15 pairs of bicycle exercise tests could 
be evaluated in the apheresis and medication groups, 
respectively (Table 4). The patient from the apheresis 
group who died early in the study was excluded from 
analysis. At baseline, no differences in exercise tolerance 
by bicycle tests were found between both groups. After 1 
year and 2 years of treatment, a significant increment in 
time to 0.1 mV ST depression (ST-time) was observed in 
the apheresis group, accompanied by a significant de­
crease of the ST depression at maximal load (ST-max), 
whereas no changes were found in the medication group 
(Fig 1). These differences remained highly significant 
when corrected for the product of systolic blood pres­
sure and heart rate at maximal exercise and when the 
patients who had PTC A, CABG, or myocardial infarc­
tion were excluded (data not shown). None of the 
patients with a negative or inconclusive test showed 
conversion to a positive exercise test.
After exclusion of the patients who had a CABG 
procedure, two and six paired exercise thallium scintig­
raphies were available in the apheresis and medication 
groups, respectively, The value of the analysis of the 
scans is limited because of the small numbers. However, 
no differences were found in the number of segments 
with perfusion defects or redistribution within and be­
tween both groups (data not shown).
Quantitative Analysis of Coronary Angiography
The coronary angiograms of 20 patients could be 
evaluated in both groups. The two patients who could 
not be evaluated at follow-up included one assigned to 
the apheresis group who underwent CABG surgery and 
died within 3 months after the start of the study and one 
assigned to the medication group whose film quality was 
insufficient for paired analysis. Bypass grafts were in­
cluded in the analysis: 16 and 22 segments in the 
apheresis and medication groups, respectively, Paired 
measurements were available on 351 segments, with a 
mean of 8.8±2.2 (range, 4 to 15) segments analyzed per 
patient in both groups. No significant differences were 
found for the MSD and the MOD between and within 
the groups analyzed on patient or on segment basis 
(Table 5). The mean change per patient in percent 
stenosis was not different for both groups. On a segment 
basis, the analysis of the changes in percent stenosis 
showed a comparable reduction in both minor (20% to 
50%) and major (>50%) stenotic segments in both 
treatment groups (Table 5). However, in the apheresis 
group, the total number of lesions was decreased as the 
result of the disappearance (<20%) of 40 minor steno­
ses versus 20 in the medication group (P=,005), whereas 
23 versus 32 new stenoses were found, respectively 
(P=.19). By categorical approach, 9 patients in the 
apheresis group and 11 patients in the medication group
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Fig 1. Time to 1 mm (=0.1 mV) ST depression (ST-time in 
seconds) and maximal ST depression (ST-max in millimeters) in 
the LDL-apheresis group (n=17) versus the medication group 
(n=15) at baseline, after 1 year, and after 2 years of treatment. 
Asterisks denote significant differences: *.01<P<.05; 
**.001<P<.01; ***P<.001 (t test).
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Table 5. Results of Quantitative Computer Analysis of the Coronary Angiographies: Baseline and at the End 
of the Study
Apheresis Medication Only Difference
No. Baseline Follow-up Change No. Baseline Follow-up Change P
Per-patient analysis 20 20
Mean segment
diameter, mm 2.65±0.49 2.63±0,41 -0,01+0.16 2.58±0.51 2.60±0.48 0.03±0.16 .46
Minimal obstruction
diameter, mm 1.93+0.43 1.92+0.40 -0.01+0.13 1.89+0.50 1,90±0.46 0.01 ±0.11 .54
Percent stenosis
20%-50% 31.3+5.5 31.9±5.8 0.6±2.3 33.2±5.4 33,9±4.4 0.7±3.5 .65
>50% ♦  *  f t  4  1 T  P  * ■ f  ■ é  m  é
Per-segment analysis 173 178
Mean segment
diameter, 2.59±0.96 2.59±0.95 0.00 ±0.24 2.56±1.00 2.59 ±0.97 0.02+0.24 .29
mm
Minimal obstruction
diameter, mm 1.93+0.93 1.92+0.92 -0.01+0.26 1.89+0.98 1.90±0.94 0.01+0.26 .48
Percent stenosis
20%-50% 177 30.1+7.6 29.6+11.4 —0.6+8.4 161 32.8±8.6 32.0±11.5 -0.8±9.1 .82
>50% 18 56.0±7.6 52.5+12,4 -3.5 ±9.5 25 57.0+6.6 52.6±11.8 -4.5±12.3 .78
Data are mean±SD. Change indicates difference of follow-up minus baseline; P, probability value of treatment effect comparing changes in the apheresis 
group with the changes in the medication group (t test). In the per-patient analysis, mean percent stenoses >50% were not present.
were classified as progressors. Two and 5 patients were 
regressors, respectively, and the remaining men showed 
stable disease.
Correlations
Of baseline variables, total cholesterol (/■=-,51, 
P = ,01), LDL cholesterol (7-= —.48, P = .02), ratio of 
LDL/HDL cholesterol (r= -.63 , P=.001), and apo B 
(r= —.49, P=.01) were correlated with time to 0.1 mV 
ST-segment depression. Relative changes from baseline 
of total cholesterol and LDL cholesterol were also 
significantly correlated with the change in time to 0.1 
mV ST-segment depression on the exercise EGG (Table 
6). No correlations were found between baseline and in­
trial lipid and lipoprotein levels and MSD or percent 
stenosis. Only mean in-trial concentrations of total cho­
lesterol, LDL cholesterol, ratio of LDL/HDL cholester­
ol, and apo B were associated with the percent change in 
MOD (Table 6 and Fig 2). No correlations were found 
between time to 0.1 mV ST-segment depression on the 
exercise ECG and MOD. An association was found
Table 6. Correlations Between Lipids and 
Lipoproteins and Some Outcome Variables, Expressed 
as Percent Change From Baseline
Change in 
ST-Time
Change in 
MOD
r P r P
Change from baseline
Total cholesterol .42 .04 .25 .12
LDL cholesterol .52 .01 .30 .06
LDL/HDL ratio .39 .06 .35 .03
Apo B .39 .06 .22 .16
Mean in-trial concentrations
Total cholesterol -.34 .10 -.41 .009
LDL cholesterol -.37 .08 -.43 .006
LDI7HDL ratio -.30 .15 -.37 .01
Apo B -.36 .09 -.35 .03
between maximal ST depression on the exercise ECG 
and MOD at baseline (r= — .48, P=.006) and after 2 
years of treatment (/*— —.39, P=.03).
Treatment Side Effects
No significant differences were found between and 
within the groups for serum creatinine levels, fasting 
blood glucose, alkaline phosphatase, and leukocyte 
counts. The patients on apheresis experienced a signifi­
cant fall in hemoglobin level from 9.2±0,6 mmol • L_1 to 
8.6±0,6 mmol • L“1 ( —6.0±5.8%) as a result of the 
procedure. A nonspecific acute loss of 12% of serum 
protein levels was observed directly after apheresis, 
without trend in change of pretreatment levels. Twelve 
of 1039 (1.2%) apheretic procedures were complicated 
by an episode of hypotension (systolic blood pressure 
<80 mm Hg) not leading to discontinuation of the 
treatment. No bleeding complications were observed the 
first days after LDL-apheresis. Only two sessions in 1 
patient had to be interrupted due to an “anaphylactoid” 
reaction caused by the temporary administration of an 
ACE inhibitor,43’'14 During the administration of simva-
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statin, no subjective adverse experiences were observed. 
Episodes with aminotransferase levels >3 times the 
upper limit (^30 U • L~J) did not occur: 3 patients in the 
apheresis group and 1 patient in the medication group 
had ^50%  of the measurements of alanine aminotrans­
ferase (ALAT) between 31 and 99 U ■ L~]. Creatine 
phosphokinase (CK) levels were elevated in 3 patients in 
both groups in ^50%  of the measurements (range, 101 
to 468 U ■ L '1; upper limit of normal <100 U * L“1). 
None of the patients had to discontinue the administra­
tion of simvastatin.
D iscussion
The LAARS trial was performed to evaluate whether 
aggressive lipid lowering using LDL-apheresis in men 
with extensive CAD, of whom the majority had familial 
hypercholesterolemia (FH), will exert better retardation 
of the progression of coronary atherosclerosis in com­
parison to conventional treatment. The study showed 
that the addition of biweekly LDL-apheresis to lipid 
lowering treatment with an HMG-CoA reductase inhib­
itor improved the ischemic threshold, whereas an equal 
effect in angiographically derived measures for coronary 
atherosclerosis was observed in both groups, in whom 
progression of disease would be usual.43’46
The accepted indication for LDL-apheresis is resis­
tance to drug treatment in patients with CAD,47 In 
LAARS, LDL-apheresis was used as a method to lower 
LDL cholesterol more aggressively in subjects who were 
not drug resistant. Our results confirm the usefulness of 
extracorporeal therapy in achieving and maintaining 
extremely low levels of LDL cholesterol while preserving 
HDL, with an acceptable safety profile, as has recently 
been shown.3S-47 The reduction of baseline LDL choles­
terol from levels of 7.8 mmol ■ L“J by 63% in the 
apheresis group is in keeping with other studies using 
LDL-apheresis.22’48’49 On the other hand, LDL reduction 
from 7.9 mmol * L“1 by 47% in the medication group 
may be considered a good response in comparison to 
recent studies using HMG-CoA reductase inhibitors, 
which is probably the result of frequent monitoring of 
our patients,5'8,10,11 Since LDL-apheresis entails a major 
commitment for the patient and medical community, 
these latter results stress that only primary hypercholes- 
terolemic patients with established CAD refractory to 
drug treatment should be treated with LDL-apheresis.
Five prospective trials that include angiographic end 
points in patients with severe hypercholesterolemia us­
ing LDL-apheresis-containing protocols to lower LDL 
cholesterol have recently been described.38*48-51 The FH 
Regression Study38 and our study are the only random­
ized ones. Both studies show no further improvement of 
the angiographic end points by the addition of LDL- 
apheresis to conventional lipid lowering treatment. 
However, changes in measures for diffuse atheroscle­
rotic disease (MSD) and focal disease (MOD and % 
stenosis) in both studies were comparable to pooled data 
from intervention groups of five recent angiographic 
regression studies5*7’8’10,11 using HMG-CoA reductase 
inhibitors, as has been described by Thompson et al.38 
Therefore, intermittent LDL reduction by apheresis 
induces arrest of progression of angiographically visible 
lesions comparable to drug treatment.
Although LAARS demonstrated a correlation between 
the change in MOD and mean in-trial concentrations of
LDL, it is not clear why further LDL lowering in the 
apheresis group did not result in more pronounced mean 
changes in angiographic outcome measures in comparison 
to the medication group. In contrast to the FH Regression 
Study,38 LDL cholesterol levels in the apheresis group from 
our study were more reduced than in the medication 
group. In the first study, mean LDL cholesterol levels were
3.2 mmol • L '1 in the apheresis group versus 3.4 
mmol • L~E in the medication group, whereas in our study, 
levels of 3.0 and 4.1 mmol ■ L"1 were reached, respectively. 
The significance of the observed correlation between 
MOD and in-trial LDL in our study suggests that the 
nonsustained reduction of LDL cholesterol due to the 
rebound after LDL-apheresis does not play a role.38-52 
Sample size and the duration of the intervention may be 
more important, because expected changes in percent 
stenosis after a relatively short period of intervention have 
been shown to be too optimistic.14 Recent data from the 
Multicentre Anti-Atheroma Study (MAAS)11 and the 
Scandinavian Simvastatin Survival Study (4S)16 support this 
view. MAAS showed a trend toward improvement, but no 
statistical differences, of the angiographic measures MOD 
and MSD after 2 years of simvastatin treatment compared 
with placebo, whereas after 4 years of treatment significant 
differences were observed angiographically.11 The 4S trial 
showed that the effect of simvastatin treatment on coronary 
events started after 1 year of therapy and increased steadily 
thereafter.16 Therefore, it is not unexpected that differ­
ences between the apheresis and medication groups in 
LAARS were not angiographically detectable.
The reduction of time-averaged levels of Lp(a) in the 
apheresis group from that in LAARS was much less in 
comparison to LDL. This may be caused by an increase 
of Lp(a) concentrations associated with the administra­
tion of simvastatin, which was also found in the medica­
tion group, and has been confirmed by others.38,53 How­
ever, an increased rebound of Lp(a) after apheresis in 
comparison to LDL may also play a role.31’54 One of the 
objectives of the FH Regression Study38 was to verify 
whether lowering of Lp(a) concentrations by apheresis 
was associated with further reduction of the percent 
diameter stenosis of coronary arteries. No benefit could 
be shown of reducing Lp(a) levels in patients whose 
LDL cholesterol levels had been effectively lowered by 
drug therapy or apheresis. Our data confirm these 
results, particularly because the differences in mean in- 
trial LDL cholesterol concentrations in the medication 
and apheresis groups were greater than those in the FH 
Regression Study, with comparable changes in Lp(a) 
levels in both studies. So, the question of the clinical 
relevance of increased Lp(a) levels during treatment 
with an HMG-CoA reductase inhibitor seems current.
Naturally occurring progression of CAD is mainly 
seen in the formation of new coronary lesions and less in 
growth of preexisting ones, and progression of the latter 
is correlated with high cholesterol levels46 Most regres­
sion studies showed the greatest benefit in atheroma 
obstructing >50% of the lumen,13 and some reported 
that mainly smaller lesions responded.9’11-55 In the pres­
ent study, percent stenosis remained almost unchanged 
during the 2 years of treatment (97% of stenoses showed 
changes in degree of <20%), and no preference for 
changes in severe (>50%) stenoses was observed. It was 
found, however, that more aggressive lipid lowering with 
LDL-apheresis resulted in the disappearance of more
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mild to moderate (20% to 50%) lesions, whereas the 
formation of new lesions appeared to be comparable 
between the apheresis and medication groups. There­
fore, our data appear to be in favor of reducing more 
early lesions as a response to aggressive lipid lowering of 
relatively short duration, as has also been shown in the 
Canadian Coronary Atherosclerosis Intervention Study 
(CCAIT) and MAAS.10*11 This may be important, since 
early lipid-rich lesions with a fine fibrous cap are prone 
to rupture and lead to thrombotic occlusions and con­
sequent clinical events.56 Therefore, more aggressive 
lipid lowering appears to improve stabilization and 
regression of these lesions.
A remarkable observation of our study was the im­
provement in ergometric bicycle tests. This has also been 
found in some uncontrolled studies while applying LDL- 
apheresis and may be present within weeks from the 
start of treatment.50*51 We observed significant improve­
ment of the exercise tests after 1 year of treatment, 
which further increased after 2 years. Changes in the 
time to 0.1 mV ST depression after 2 years of treatment 
were also significantly correlated with the amount of 
LDL reduction. These findings and the angiographic 
ones suggest that mechanisms other than changes in 
stenosis play a role in the outcome of the exercise tests. 
Indeed, cholesterol lowering with HMG-CoA reductase 
inhibitors has been shown to improve endothelium- 
dependent relaxation in the coronary arteries of patients 
with atherosclerosis.57 On the other hand, improved 
blood flow by changes in blood rheology induced by 
LDL-apheresis may also contribute to the improvement 
of coronary flow.58 However, reductions of fibrinogen 
and most other coagulation factors do not last longer 
than 24 to 48 hours,59 whereas changes in blood viscosity 
have been measured until 1 week after an apheresis 
using dextran sulfate adsorption.60 Since the follow-up 
assessments at the end of the study in LAARS were 
done 3 to 4 weeks after the last LDL-apheresis, Theo­
logical changes did not confound our results. This indi­
cates that functional improvements of the coronary 
vasomotor function on a level beyond the resolution of 
the angiogram may precede anatomic changes in se­
verely stenotic coronary arteries.27*61*62 Therefore, func­
tional measures should be considered as additional and 
possibly more sensitive outcome variables for short-term 
angiographic studies. In our study, we also assessed the 
videodensitometric measurements of the blood flow in 
the coronary microcirculation as a functional primary 
outcome variable. These data are presently being ana­
lyzed and will be published separately.
It has been shown that culprit lesions in unstable 
angina have increased vasoreactivity, which is responsi­
ble for the risk of recurrence of unstable angina or 
infarction.63 Plaque stabilization by lipoprotein manipu­
lation may require more than 1 year of aggressive 
treatment before a significant reduction in clinical events 
can be documented.15 In our study, we were confronted 
with a few myocardial infarctions in the apheresis group 
in the early phase of the study, a difference with the 
medication group that may be associated with the use of 
anticoagulants or platelet aggregation inhibitors. It must 
be emphasized that our study was not designed to 
evaluate the clinical events. However, in combining both 
episodes of unstable angina and myocardial infarctions, 
no differences between both treatment groups were
observed. Considering the natural progression of CAD, 
it is notable that both treatment groups showed less 
events than expected in the second year of treatment. 
This observation supports the notion that the effect of 
cholesterol lowering on functional improvement pre­
cedes anatomic regression of atherosclerosis.27
Conclusions
Combined LDL-apheresis and cholesterol lowering 
drugs in patients at high risk for cardiovascular events 
arrests further progression of CAD and induces func­
tional improvement of the coronary blood flow. Studies 
of longer intervention periods are warranted to confirm 
these findings and observe the expected angiographic 
regression of CAD. However, only primary hypercholes- 
terolemic patients with established CAD refractory to 
drug treatment should be treated with LDL-apheresis.
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